Clinical Trials

15 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms, Respiratory Tract Neoplasms

NCT01636908 2021-04-15

ICK

Phase NA Completed

43 enrolled

Neoplasms

NCT03403049 2020-04-22

Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer

14 enrolled

Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT00848718 2019-11-12

MK-2206-003

77 enrolled 24 charts

Neoplasms

NCT01545947 2019-11-12

Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer

76 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT01472016 2017-11-21

Study of ABT-700 in Subjects With Advanced Solid Tumors

74 enrolled

Neoplasms

NCT01192165 2017-11-13

Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

169 enrolled

Neoplasms

NCT00369512 2017-05-30

RAD0503

15 enrolled 9 charts

Carcinoma, Squamous Cell, Neoplasms

NCT01482377 2017-01-27

A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin

145 enrolled

Neoplasms

NCT00705874 2016-07-21

Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma

172 enrolled 13 charts

Lymphoid

Lymphoma, Neoplasms

NCT00207077 2015-10-28

Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors

33 enrolled

Neoplasms

NCT00585377 2015-09-24

Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer

50 enrolled 7 charts

Neoplasms

NCT00109265 2015-07-02

A Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast Cancer During or Following Chemotherapy

Breast

Breast Neoplasms, Neoplasms

NCT01727869 2015-04-06

Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer

56 enrolled

Neoplasms

NCT01565538 2014-09-15

Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma

123 enrolled 9 charts

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT00884845 2014-03-26

Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors

35 enrolled

Neoplasms

NCT00725634 2014-01-27

P05538

41 enrolled

LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Neoplasms, Plasma Cell

NCT00418704 2013-10-01

Elderly Independent Patients With Non Small Cell Lung Cancer (NSCLC)

Completed

100 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT00419042 2013-10-01

Elderly Dependent Patients With Non Small Cell Lung Cancer (NSCLC)

Completed

100 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT00692640 2012-03-23

Safety Study of XL147 (SAR245408) in Combination With Erlotinib in Adults With Solid Tumors

35 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT00777699 2012-02-03

Safety Study of XL765 (SAR245409) in Combination With Erlotinib in Adults With Solid Tumors

80 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT00603356 2011-09-27

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

GastrointestinalGynecologicOther solid neoplasmSarcomaThoracic

60 enrolled

Mesothelioma, Neoplasms, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

NCT00440414 2010-08-19

Trial of Pemetrexed Versus Erlotinib in Pretreated Patients With Non Small Cell Lung Cancer (NSCLC)

Phase 3 Completed

320 enrolled